What ocular side effects are associated with tirzepatide (including in patients with type 2 diabetes, obesity, or diabetic retinopathy) and what monitoring is recommended?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 18, 2026 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Ocular Side Effects of Tirzepatide

Tirzepatide is associated with an increased risk of early worsening of diabetic retinopathy (particularly progression to proliferative diabetic retinopathy), nonarteritic anterior ischemic optic neuropathy (NAION), and other optic nerve disorders, though the absolute risk remains low. 1, 2

Diabetic Retinopathy Risks

Early Worsening of Diabetic Retinopathy (EWDR)

  • Tirzepatide significantly increases the odds of new-onset proliferative diabetic retinopathy (PDR) by 2.15-fold (OR 2.15 [95% CI 1.24,3.74]) in patients with type 2 diabetes, occurring in 1.1% of tirzepatide-exposed individuals versus 0.5% of unexposed individuals. 1

  • The highest risk for retinopathy progression occurs in patients with:

    • Mild non-proliferative diabetic retinopathy (NPDR) with maculopathy (grade R1M1)
    • Moderate-to-severe NPDR with or without maculopathy (grades R2M0, R2M1) 1

  • Paradoxically, tirzepatide reduces the odds of new-onset retinopathy by 27% (OR 0.73 [95% CI 0.62,0.86]) in patients without baseline diabetic retinopathy (R0M0), and does not significantly increase progression risk in those with mild NPDR without maculopathy (R1M0). 1

Mechanism of Retinopathy Worsening

  • The rapid improvement in glycemic control achieved with tirzepatide (mean HbA1c reduction of 1.24-2.58%) may trigger EWDR through mechanisms similar to those observed with other GLP-1 receptor agonists, including subcutaneous semaglutide. 3, 1

Optic Nerve Disorders

Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)

  • Tirzepatide increases the risk of NAION by 76% (HR 1.76 [95% CI 1.01-3.07]), with 0.04% of tirzepatide-exposed patients developing NAION versus 0.02% of unexposed patients during 2-year follow-up. 2

  • Pharmacovigilance analysis identified 28 cases of ischemic optic neuropathy with tirzepatide, yielding significant disproportionality signals (ROR: 2.599 [95% CI 1.778-3.799]) and a "probable" drug-event association by Evans criteria. 4

Other Optic Nerve Disorders

  • Tirzepatide increases the risk of other optic nerve disorders by 65% (HR 1.65 [95% CI 1.18-2.31]), affecting 0.12% of exposed patients versus 0.07% of unexposed patients. 2

  • No significant associations were found with other disorders of the visual pathways beyond optic nerve involvement. 2

Monitoring Recommendations

Pre-Treatment Assessment

  • All patients with type 2 diabetes should undergo a comprehensive dilated eye examination by an ophthalmologist or optometrist shortly after diabetes diagnosis and before initiating tirzepatide. 5

  • Patients with type 1 diabetes should have an initial dilated examination within 5 years of diabetes onset. 5

High-Risk Patient Identification

  • Close monitoring of retinopathy is mandatory in patients at high risk, specifically:
    • Older individuals
    • Those with diabetes duration ≥10 years
    • Patients with any baseline diabetic retinopathy, particularly mild NPDR with maculopathy or moderate-to-severe NPDR 5, 1

Follow-Up Schedule

  • Patients with baseline retinopathy (R1M1, R2M0, R2M1) should be referred to a specialist ophthalmologist before initiating tirzepatide, as the increased odds of progression to PDR meet Early Treatment Diabetic Retinopathy Study (ETDRS) criteria for specialist referral. 1

  • During tirzepatide titration (first 16-20 weeks), assess every 4 weeks for signs of visual changes or ocular symptoms. 6

  • After reaching maintenance dose, evaluate every 3 months for any new visual symptoms or changes. 6

  • Patients with diabetic retinopathy should have annual examinations by an ophthalmologist or optometrist, with more frequent examinations if retinopathy is progressing. 5

  • Patients without retinopathy after one or more normal exams may be examined every 2-3 years. 5

Urgent Referral Criteria

  • Promptly refer patients with any of the following to an ophthalmologist experienced in diabetic retinopathy management:

    • Any level of macular edema
    • Severe non-proliferative diabetic retinopathy (NPDR)
    • Any proliferative diabetic retinopathy (PDR) 5

  • Immediate ophthalmology evaluation is required for:

    • Sudden vision loss
    • New visual field defects
    • Symptoms suggestive of NAION (sudden painless monocular vision loss, altitudinal visual field defect) 2, 4

Clinical Pitfalls and Caveats

  • The absolute risk of NAION and optic nerve disorders remains low (0.04-0.12%), but the relative risk increase is clinically significant and warrants informed consent discussion before initiating therapy. 2, 4

  • Do not withhold tirzepatide from patients without baseline retinopathy, as these patients actually have reduced odds of developing new-onset retinopathy. 1

  • The presence of retinopathy is not a contraindication to aspirin therapy for cardioprotection, as aspirin does not increase the risk of retinal hemorrhage. 5

  • Patients should be counseled that visual symptoms require immediate medical attention, as both NAION and proliferative diabetic retinopathy can cause permanent vision loss if not promptly addressed. 2, 4

  • Optimize blood pressure control concurrently, as hypertension independently increases the risk and progression of diabetic retinopathy. 5

References

5
Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

6
Guideline

Tirzepatide for Weight Loss: Efficacy and Safety

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Related Questions

What are the recommendations for using Tirzepatide (a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist) in patients with type 2 diabetes who are at risk of or have diabetic retinopathy?
Can a non-diabetic patient on metformin (biguanide) start tirzepatide (dual GIP and GLP-1 receptor agonist) concurrently?
What is the equivalent dose of tirzepatide (dual GIP and GLP-1 receptor agonist) for a patient taking 1 mg of Ozempic (semaglutide) weekly?
What is the comparison between semaglutide (GLP-1 receptor agonist) and tirzepatide (dual GIP and GLP-1 receptor agonist) for treatment?
Can a 61-year-old obese man with prediabetes (HbA1c 6.2%) and a frontal gait disorder from prior brain cancer be prescribed semaglutide (Ozempic/Wegovy) or tirzepatide (Mounjaro) for weight loss despite not having diagnosed type 2 diabetes?
Can I take oral estradiol (Estrace) with tea or coffee while on levothyroxine, and do I need to wait before dosing?
For a 15‑year‑old Caucasian female with severe, treatment‑refractory major depressive disorder and active suicidal intent who has failed prior interventions, is risperidone monotherapy appropriate to limit medication access, or should an antidepressant such as fluoxetine or bupropion be initiated instead?
In an otherwise healthy adult traveler to Thailand presenting with nausea and vomiting, what is the most common cause and what is the recommended initial management?
In an otherwise healthy outpatient with community‑acquired pneumonia who tested negative for Mycoplasma pneumoniae, should I still prescribe azithromycin for atypical coverage?
What is the recommended treatment strategy for an adult patient admitted with acute uncomplicated cystitis (type 2 urinary‑tract infection) from initiation of therapy through discharge?
What is the first‑line management for a plantar callus in an adult, and how should treatment be modified for patients with diabetes, peripheral neuropathy, peripheral arterial disease, or signs of infection?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question